Literature DB >> 31041786

Macrophages as Key Players during Adipose Tissue-Liver Crosstalk in Nonalcoholic Fatty Liver Disease.

Hannelie Korf1, Markus Boesch1, Lore Meelberghs1, Schalk van der Merwe1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries that could lead to serious health problems including liver failure, cancer, or death. The term NAFLD includes a spectrum of disease states with histological features ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). A key aspect within this research field is the identification of pathogenic factors that trigger inflammation, thus fueling the transition from nonalcoholic fatty liver to NASH. These inflammatory triggers may originate from within the liver as a result of innate immune cell activation and/or hepatocyte injury. Additionally, they may originate from other sites such as adipose tissue or the intestinal tract. In the current review, the authors will primarily focus on events within adipose tissue which may be of importance in triggering the disease progression. They specifically focus on the role of adipose tissue macrophages during NAFLD pathogenesis and how microenvironmental factors may shape their metabolic profile. They further dissect how redirecting the macrophage's metabolic profile alters their immunological functions. Finally, they discuss the opportunities and challenges of targeting macrophages to interfere in disease progression. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31041786     DOI: 10.1055/s-0039-1687851

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  8 in total

Review 1.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

Review 2.  Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

3.  Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player.

Authors:  Robim M Rodrigues; Yukun Guan; Bin Gao
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 19.456

4.  A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice.

Authors:  Weimin Guo; Dayong Wu; Maria C Dao; Lijun Li; Erin D Lewis; Edwin F Ortega; Heesun Eom; Michael Thomas; Mariana Nikolova-Karakashian; Mohsen Meydani; Simin N Meydani
Journal:  J Nutr       Date:  2020-11-19       Impact factor: 4.798

Review 5.  Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Authors:  Hannah K Drescher; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

6.  Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals.

Authors:  Di-Shuang Hu; Sheng-Hao Zhu; Xu Li; Qin-Fen Chen; Chun-Jing Lin; Dan-Hong Fang; Jian-Sheng Wu
Journal:  Can J Gastroenterol Hepatol       Date:  2019-12-19

7.  The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury.

Authors:  Shahrbanoo Keshavarz Azizi Raftar; Fatemeh Ashrafian; Abbas Yadegar; Arezou Lari; Hamid Reza Moradi; Arefeh Shahriary; Masoumeh Azimirad; Helia Alavifard; Zhaleh Mohsenifar; Mehdi Davari; Farzam Vaziri; Arfa Moshiri; Seyed Davar Siadat; Mohammad Reza Zali
Journal:  Microbiol Spectr       Date:  2021-09-22

Review 8.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.